These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 21993078)

  • 1. Gynecologic effects of arzoxifene in postmenopausal women with osteoporosis or low bone mass.
    Goldstein SR; Bhattoa HP; Neven P; Cox DA; Dowsett SA; Alam J; Sipos A; Muram D
    Menopause; 2012 Jan; 19(1):41-7. PubMed ID: 21993078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of arzoxifene on bone, lipid markers, and safety parameters in postmenopausal women with low bone mass.
    Downs RW; Moffett AM; Ghosh A; Cox DA; Dowsett SA; Harper K
    Osteoporos Int; 2010 Jul; 21(7):1215-26. PubMed ID: 19798460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of arzoxifene on bone mineral density and endometrium in postmenopausal women with normal or low bone mass.
    Bolognese M; Krege JH; Utian WH; Feldman R; Broy S; Meats DL; Alam J; Lakshmanan M; Omizo M
    J Clin Endocrinol Metab; 2009 Jul; 94(7):2284-9. PubMed ID: 19351734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Arzoxifene versus raloxifene: effect on bone and safety parameters in postmenopausal women with osteoporosis.
    Kendler DL; Palacios S; Cox DA; Stock J; Alam J; Dowsett SA; Zanchetta J
    Osteoporos Int; 2012 Mar; 23(3):1091-101. PubMed ID: 21374068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of the safety of long-term bazedoxifene treatment on the reproductive tract in postmenopausal women with osteoporosis: results of a 7-year, randomized, placebo-controlled, phase 3 study.
    Palacios S; de Villiers TJ; Nardone Fde C; Levine AB; Williams R; Hines T; Mirkin S; Chines AA;
    Maturitas; 2013 Sep; 76(1):81-7. PubMed ID: 23871271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bazedoxifene, a selective estrogen receptor modulator: effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporotic postmenopausal women.
    Archer DF; Pinkerton JV; Utian WH; Menegoci JC; de Villiers TJ; Yuen CK; Levine AB; Chines AA; Constantine GD
    Menopause; 2009; 16(6):1109-15. PubMed ID: 19543129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Breast cancer incidence in postmenopausal women with osteoporosis or low bone mass using arzoxifene.
    Powles TJ; Diem SJ; Fabian CJ; Neven P; Wickerham DL; Cox DA; Muram D; Agnusdei D; Dowsett SA; Amewou-Atisso M; Cummings SR
    Breast Cancer Res Treat; 2012 Jul; 134(1):299-306. PubMed ID: 22484799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years.
    Jolly EE; Bjarnason NH; Neven P; Plouffe L; Johnston CC; Watts SD; Arnaud CD; Mason TM; Crans G; Akers R; Draper MW
    Menopause; 2003; 10(4):337-44. PubMed ID: 12851517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Arzoxifene for prevention of fractures and invasive breast cancer in postmenopausal women.
    Cummings SR; McClung M; Reginster JY; Cox D; Mitlak B; Stock J; Amewou-Atisso M; Powles T; Miller P; Zanchetta J; Christiansen C
    J Bone Miner Res; 2011 Feb; 26(2):397-404. PubMed ID: 20658564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bazedoxifene effects on the reproductive tract in postmenopausal women at risk for osteoporosis.
    Pinkerton JV; Archer DF; Utian WH; Menegoci JC; Levine AB; Chines AA; Constantine GD
    Menopause; 2009; 16(6):1102-8. PubMed ID: 19546825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Third generation selective estrogen receptor modulators: benefits beyond bone. II, endometrial action].
    Calaf Alsina J; Coronado Martín PJ
    Med Clin (Barc); 2013 Mar; 140(6):266-71. PubMed ID: 23276611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endometrial lesions causing uterine bleeding in postmenopausal women receiving raloxifene.
    Tsalikis T; Zepiridis L; Zafrakas M; Dinas K; Bontis J
    Maturitas; 2005 Jun; 51(2):215-8. PubMed ID: 15917163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Arzoxifene as therapy for endometrial cancer.
    Burke TW; Walker CL
    Gynecol Oncol; 2003 Aug; 90(2 Pt 2):S40-6. PubMed ID: 12928005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation.
    Cummings SR; Eckert S; Krueger KA; Grady D; Powles TJ; Cauley JA; Norton L; Nickelsen T; Bjarnason NH; Morrow M; Lippman ME; Black D; Glusman JE; Costa A; Jordan VC
    JAMA; 1999 Jun; 281(23):2189-97. PubMed ID: 10376571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endometrial safety: a key hurdle for selective estrogen receptor modulators in development.
    Pinkerton JV; Goldstein SR
    Menopause; 2010; 17(3):642-53. PubMed ID: 20107426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current and emerging pharmacologic therapies for the management of postmenopausal osteoporosis.
    Lewiecki EM
    J Womens Health (Larchmt); 2009 Oct; 18(10):1615-26. PubMed ID: 19857095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of raloxifene on bone mineral density and biochemical markers of bone turnover in Japanese postmenopausal women with osteoporosis: results from a randomized placebo-controlled trial.
    Morii H; Ohashi Y; Taketani Y; Fukunaga M; Nakamura T; Itabashi A; Sarkar S; Harper K
    Osteoporos Int; 2003 Oct; 14(10):793-800. PubMed ID: 12955333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of raloxifene on serum triglycerides in postmenopausal women: influence of predisposing factors for hypertriglyceridemia.
    Mosca L; Harper K; Sarkar S; O'Gorman J; Anderson PW; Cox DA; Barrett-Connor E
    Clin Ther; 2001 Sep; 23(9):1552-65. PubMed ID: 11589267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Postmenopausal Evaluation and Risk Reduction With Lasofoxifene (PEARL) trial: 5-year gynecological outcomes.
    Goldstein SR; Neven P; Cummings S; Colgan T; Runowicz CD; Krpan D; Proulx J; Johnson M; Thompson D; Thompson J; Sriram U
    Menopause; 2011 Jan; 18(1):17-22. PubMed ID: 20689465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Breast cancer chemoprevention phase I evaluation of biomarker modulation by arzoxifene, a third generation selective estrogen receptor modulator.
    Fabian CJ; Kimler BF; Anderson J; Tawfik OW; Mayo MS; Burak WE; O'Shaughnessy JA; Albain KS; Hyams DM; Budd GT; Ganz PA; Sauter ER; Beenken SW; Grizzle WE; Fruehauf JP; Arneson DW; Bacus JW; Lagios MD; Johnson KA; Browne D
    Clin Cancer Res; 2004 Aug; 10(16):5403-17. PubMed ID: 15328178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.